ROADS Phase 3 Clinical Trial Data Presented at ASCO26 Show GammaTile® Provides Superior Tumor Control Leading to Patients Living Longer Without Recurrence Compared to Standard of Care in Newly Diagnosed Operable Brain Metastases
Results support GammaTile (cesium-131 collagen tile-based radiation therapy, or TBRT) as a new standard of care for achieving optimal outcomes in this patient population Superior efficacy achieved without increased side effects Data presented in late-breaking abstract at the 2026 Annual...
Results support GammaTile (cesium-131 collagen tile-based radiation therapy, or TBRT) as a new standard of care for achieving optimal outcomes in this patient population Superior efficacy achieved without increased side effects Data presented in late-breaking abstract at the 2026 Annual...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.